Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer
Open accessThe DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
Nanotheranostics have demonstrated the development of advanced platforms that can diagnose brain cancer at early stages, initiate first-line therapy, monitor it, and if needed, rapidly start subsequent treatments. In brain nanotheranostics, therapeutic as well as diagnostic entities are loaded in a single nanoplatform, which can be further developed as a clinical formulation for targeting various modes of brain cancer. In the present review, we concerned about theranostic nanosystems established till now in the research field. These include gold nanoparticles, carbon nanotubes, magnetic nanoparticles, mesoporous silica nanoparticles, quantum dots, polymeric nanoparticles, upconversion nanoparticles, polymeric micelles, solid lipid nanoparticles and dendrimers for the advanced detection and treatment of brain cancer with advanced features. Also, we included the role of three-dimensional models of the BBB and cancer stem cell concept for the advanced characterization of nanotheranostic systems for the unification of diagnosis and treatment of brain cancer. In future, brain nanotheranostics will be able to provide personalized treatment which can make brain cancer even remediable or at least treatable at the primary stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Applications of magnetic nanoparticles in biomedicine
Pankhurst, Q. A., Connolly, J., Jones, S. K., & Dobson, J. (2003) · Journal of Physics D: Applied Physics · doi:10.1088/0022-3727/36/13/201 · Cited by 5,881 · cited 3×
“Owing to the magnetic response, iron oxide core facilitates the magnetic targeted delivery [84, 85].”
BackgroundAstrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 1×
“BBB is an active functional element composed of brain endothelial cells, astrocytes and pericytes as well [64].”
BackgroundUpconversion and Anti-Stokes Processes with f and d Ions in Solids
Auzel, F. (2004) · Chemical Reviews · doi:10.1021/cr020357g · Cited by 5,098 · cited 1×
“In particular, lanthanide-based UCNPs are reported as highly safer materials for nanotheranostic purposes and are quickly eliminated by hepatobiliary and renal excretion routes [106].”
BackgroundPLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806 · cited 1×
“These PLGA nanoparticles were transported by pinocytosis and also by clathrin-mediated endocytosis [114].”
BackgroundNanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901 · cited 1×
“Second, nanocarriers are competent enough to improve the pharmacokinetics and to enhance the biodistribution of existing therapeutic moieties to the target tissues, so that can improve efficiency [27].”
BackgroundOstrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou223 · Cited by 1,718
Nanoparticle-based theranostic agents
Xie, J., Lee, S., & Chen, X. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.009 · Cited by 1,422 · cited 4×
“The loading of a therapeutic molecule is accomplished by electrostatic interaction or covalent conjugation [17, 61, 62].”
BackgroundInfluentialImaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248 · cited 1×
“PET can more efficiently characterize brain tumors by investigating metabolic processes such as receptor binding, DNA synthesis or enzyme activity, oxygen metabolism and blood flow [54-57].”
BackgroundThe unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy
Doane, T. L., & Burda, C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15260f · Cited by 1,098
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947 · cited 1×
“At present, PMs are successfully being applied in preclinical as well as clinical studies [119-122].”
BackgroundChertok, B., Moffat, B. A., David, A. E., Yu, F., Bergemann, C., Ross, B. D., & Yang, V. C. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.050 · Cited by 900 · cited 1×
“Hence, these nanosystems proved to be a favorable channel for the targeted drug delivery [86].”
BackgroundLammers, T., Aime, S., Hennink, W. E., Storm, G., & Kiessling, F. (2011) · Accounts of Chemical Research · doi:10.1021/ar200019c · Cited by 870 · cited 1×
“PET can more efficiently characterize brain tumors by investigating metabolic processes such as receptor binding, DNA synthesis or enzyme activity, oxygen metabolism and blood flow [54-57].”
BackgroundAdvances in polymeric micelles for drug delivery and tumor targeting
Kedar, U., Phutane, P., Shidhaye, S., & Kadam, V. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.05.005 · Cited by 791
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733 · cited 1×
“The National Institute of Health (NIH) in the USA described nanomedicine as utilization of nanotechnology in the diagnosis, therapy with simultaneous monitoring on biological systems [26].”
BackgroundA new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728 · cited 1×
“, a model of triple co-cultured brain endothelium, astrocytes and pericytes) [65-67].”
BackgroundMesoporous silica nanoparticles in medicine—Recent advances
Mamaeva, V., Sahlgren, C., & Lindén, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 707
Liu, Y., Miyoshi, H., & Nakamura, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22709 · Cited by 620
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615 · cited 2×
“4 and 4-fold increased, respectively [128, 129].”
BackgroundAnti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., Thorsen, F., Taxt, T., Bartos, M., Jirik, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014480108 · Cited by 606 · cited 1×
“Although effective nanotheranostics for the treatment of brain cancer have been established over the time, most of them are still under investigations [20-23].”
BackgroundMuthu, M. S., Leong, D. T., Mei, L., & Feng, S.-S. (2014) · Theranostics · doi:10.7150/thno.8698 · Cited by 603 · cited 6×
“Some of them are considered as self-theranostic nanomedicines or platforms [18].”
BackgroundInfluentialSelf-citationNanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Parhi, P., Mohanty, C., & Sahoo, S. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.010 · Cited by 573 · cited 1×
“The traditional methods for treatment of cancer include surgical excision, radiation therapy and chemotherapy [40, 41].”
MethodDendrimers: Emerging polymers for drug-delivery systems
Nanjwade, B. K., Bechra, H. M., Derkar, G. K., Manvi, F. V., & Nanjwade, V. K. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.07.008 · Cited by 542 · cited 2×
“Compared with other delivery systems, they often show advantages in size uniformity, reduced macrophage uptake, rapid cellular entry, target ability and more extensive passage across biological membranes by transcytosis [131, 133].”
BackgroundCancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 537 · cited 1×
“Such improvements comprise early detection and therapy regimens which shall be more precisely taken up by brain cancer cells and also possess lessened off- target toxicity [24,25].”
BackgroundUpconversion nanoparticles: synthesis, surface modification and biological applications
Wang, M., Abbineni, G., Clevenger, A., Mao, C., & Xu, S. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.02.013 · Cited by 528
Robinson, J. T., Welsher, K., Tabakman, S. M., Sherlock, S. P., Wang, H., Luong, R., & Dai, H. (2010) · Nano Research · doi:10.1007/s12274-010-0045-1 · Cited by 525 · cited 1×
“CNTs can ameliorate the chemotherapy of brain tumors which offer better applications in clinical practices [96].”
BackgroundNanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504 · cited 3×
“As a matter of fact, novel therapeutic and diagnostic principles, advanced diagnostics and novel targeted approaches can be unified and prosper with the aid of nanotechnology [34,35].”
BackgroundKievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496 · cited 1×
“‘‘Theranostic nanomedicine’’ is defined as a unified nanotherapeutic platform in which therapeutic and diagnostic functions are combined within a unique system and permits simultaneous detection, spatial targeting as well as tracking the response of therapy [18, 19, 59].”
BackgroundNanoparticles for Brain Drug Delivery
Masserini, M. (2013) · ISRN Biochemistry · doi:10.1155/2013/238428 · Cited by 489 · cited 3×
“, PLA, PLGA and their copolymers which are readily eliminated after normal metabolic pathways [15, 112].”
BackgroundTheranostic Nanomedicine for Cancer
Sumer, B., & Gao, J. (2008) · Nanomedicine · doi:10.2217/17435889.3.2.137 · Cited by 478
Recent advances in polymeric micelles for anti-cancer drug delivery
Biswas, S., Kumari, P., Lakhani, P. M., & Ghosh, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.031 · Cited by 471 · cited 2×
“Finally, use of hydrophobic drug encapsulation, biocompatible polymers, versatile targeting aspects, simple method of preparation and success rate in preclinical studies of theranostic micelles showed their clinical potential for brain cancer applications [123, 124].”
BackgroundMethodWang, X., Wang, C., Cheng, L., Lee, S.-T., & Liu, Z. (2012) · Journal of the American Chemical Society · doi:10.1021/ja300140c · Cited by 468 · cited 1×
“Indeed, gold coated, surface modified CNTs were recently developed as an optical nanotheranostic probe which showed the targeted Raman imaging potential of the biological sample using NIR laser as excitation source [97].”
BackgroundMiura, Y., Takenaka, T., Toh, K., Wu, S., Nishihara, H., Kano, M. R., Ino, Y., Nomoto, T., Matsumoto, Y., Koyama, H., et al. (2013) · ACS Nano · doi:10.1021/nn402662d · Cited by 454 · cited 1×
“The live animal imaging results showed the tumor targeting capabilities of cRGD, which suggested the active transport of cRGD facilitated transport of the drug across the vascular and blood-brain tumor barrier (BBTB) (Figure 8) [126].”
BackgroundDrug transport to brain with targeted nanoparticles
Olivier, J.-C. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.108 · Cited by 444 · cited 1×
“Using anti-transcytosis receptor peptidomimetic antibodies to BBB, brain glioma targeted PEGylated immune nanoparticles were prepared which able to deliver the anti-cancer agents into brain parenchyma without BBB permeability alteration [111, 117].”
MethodPolymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438 · cited 1×
“In one study, Poloxamer 188 coated PLGA nanoparticles containing DOX were able to cross the BBB and reduced tumor growth in the rat model [115].”
BackgroundChoi, K. Y., Liu, G., Lee, S., & Chen, X. (2012) · Nanoscale · doi:10.1039/c1nr11277e · Cited by 437 · cited 1×
“Similar to carbon nanomaterials, MSNPs possess highly ordered hexagonal structure and high internal surface areas in the range of 500 to 1200 m2/g due to periodic arrangements of mesopores (diameter in the range of 2 to 20 nm) enclosed in silica framework [61, 100].”
BackgroundGold Nanoparticle Imaging and Radiotherapy of Brain Tumors in Mice
Hainfeld, J. F., Smilowitz, H. M., O‘Connor, M. J., Dilmanian, F. A., & Slatkin, D. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.165 · Cited by 430 · cited 1×
“It showed potential to improve treatment of glioma [77, 78].”
BackgroundRen, J., Shen, S., Wang, D., Xi, Z., Guo, L., Pang, Z., Qian, Y., Sun, X., & Jiang, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.025 · Cited by 408 · cited 2×
“Once they are taken up by the cells, they may also interact with proteins and DNA to affect the cellular signaling or mechanism of other therapies [94, 95].”
BackgroundGold nanoparticles: Emerging paradigm for targeted drug delivery system
Kumar, A., Zhang, X., & Liang, X.-J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.002 · Cited by 371 · cited 1×
“These inherent optical features enable AuNPs to be used as multifarious theranostic agents for clinical applications [61, 75].”
BackgroundNanotechnology, nanomedicine, and the development of new, effective therapies for cancer
Kawasaki, E. S., & Player, A. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.03.002 · Cited by 368 · cited 1×
“The capacity of nanocarriers to deliver both drug and diagnostic molecules selectively to cancer sites at sufficient levels is an essential determinant of the efficiency of cancer diagnosis and treatment [28,29].”
BackgroundZhan, C., Gu, B., Xie, C., Li, J., Liu, Y., & Lu, W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.020 · Cited by 366 · cited 1×
“Therefore, these results indicated that c(RGDyK)-PEG-PLA micelles might be an efficient nanotheranostic system for the treatment of integrin αvβ3 over-expressed glioblastoma [125].”
BackgroundHeo, D. N., Yang, D. H., Moon, H.-J., Lee, J. B., Bae, M. S., Lee, S. C., Lee, W. J., Sun, I.-C., & Kwon, I. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.064 · Cited by 357 · cited 1×
“These were also tried against the simple NIH3T3 cells, concluding that the AuNPs-5 were found to be more efficiently interacting with the tumor cells, which was confirmed by fluorescence and cell viability analyses [79].”
MethodMulti-functional polymeric nanoparticles for tumour-targeted drug delivery
van Vlerken, L. E., & Amiji, M. M. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.2.205 · Cited by 352 · cited 1×
“PNPs are reported with various advantages in drug delivery to CNS due to their capacity of entrapping drugs thus preventing them from metabolism and excretion, and in the delivery of anti-cancer drugs across the BBB without altering the barrier characteristics [110].”
BackgroundMultifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349 · cited 11×
“The therapy in the brain cancers is limited because the desired concentration of therapeutic entities does not reach the targeted area after administration [2].”
BackgroundInfluentialCurrent Multistage Drug Delivery Systems Based on the Tumor Microenvironment
Chen, B., Dai, W., He, B., Zhang, H., Wang, X., Wang, Y., & Zhang, Q. (2017) · Theranostics · doi:10.7150/thno.16684 · Cited by 342 · cited 1×
“The traditional methods for treatment of cancer include surgical excision, radiation therapy and chemotherapy [40, 41].”
MethodTargeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.011 · Cited by 335 · cited 10×
“Danhier et al. have synthesized PTX loaded RGD-grafted PLGA-NPs to target tumor endothelium for enhanced efficacy.”
BackgroundInfluentialBrain cancer diagnosis and therapy with nanoplatforms☆
KOO, Y., REDDY, G., BHOJANI, M., SCHNEIDER, R., PHILBERT, M., REHEMTULLA, A., ROSS, B., & KOPELMAN, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.012 · Cited by 326 · cited 4×
“PNPs are solid nano sized colloidal particles in which the anti-cancer drug is either dissolved, entrapped, encapsulated, or adsorbed onto the polymer matrix [2, 9].”
BackgroundInfluentialNi, D., Zhang, J., Bu, W., Xing, H., Han, F., Xiao, Q., Yao, Z., Chen, F., He, Q., Liu, J., et al. (2014) · ACS Nano · doi:10.1021/nn406197c · Cited by 300 · cited 1×
“By this, they have maximized the accuracy of the surgical resection and preoperative diagnosis and intraoperative positioning of intracranial glioblastoma that normally possess the possible risk of incomplete excision due to the original invading nature of the glioblastoma [109] (Figure 5 and 6).”
BackgroundIn Vitro Blood–Brain Barrier Models: Current and Perspective Technologies
Naik, P., & Cucullo, L. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23022 · Cited by 288 · cited 1×
“, a model of triple co-cultured brain endothelium, astrocytes and pericytes) [65-67].”
BackgroundTheranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots
Muthu, M. S., Kulkarni, S. A., Raju, A., & Feng, S.-S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.036 · Cited by 265
Self-citationNance, E., Zhang, C., Shih, T.-Y., Xu, Q., Schuster, B. S., & Hanes, J. (2014) · ACS Nano · doi:10.1021/nn504210g · Cited by 262 · cited 1×
“Although effective nanotheranostics for the treatment of brain cancer have been established over the time, most of them are still under investigations [20-23].”
BackgroundDixit, S., Novak, T., Miller, K., Zhu, Y., Kenney, M. E., & Broome, A.-M. (2015) · Nanoscale · doi:10.1039/c4nr04853a · Cited by 262 · cited 1×
“Further, in-vitro study on cell lines exhibited a notable improvement in uptake studies of targeted formulations when compared to non-targeted particles [81] (Figure 4).”
ResultSelective Targeting of Brain Tumors with Gold Nanoparticle-Induced Radiosensitization
Joh, D. Y., Sun, L., Stangl, M., Al Zaki, A., Murty, S., Santoiemma, P. P., Davis, J. J., Baumann, B. C., Alonso-Basanta, M., Bhang, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062425 · Cited by 252 · cited 1×
“It showed potential to improve treatment of glioma [77, 78].”
BackgroundPolymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival in Vivo
Mangraviti, A., Tzeng, S. Y., Kozielski, K. L., Wang, Y., Jin, Y., Gullotti, D., Pedone, M., Buaron, N., Liu, A., Wilson, D. R., et al. (2015) · ACS Nano · doi:10.1021/nn504905q · Cited by 249 · cited 1×
“In another patent, polymethacrylic acid based nanoparticles containing polysorbate moieties were reported for targeted brain delivery [112, 113] (Figure 7).”
BackgroundSolid Lipid Nanoparticles: A Review
., S. C. V., ., S. V., & ., U. U. (2011) · Journal of Current Pharma Research · doi:10.33786/jcpr.2011.v01i04.009 · Cited by 249
Novel anti-angiogenic therapies for malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70260-6 · Cited by 246 · cited 2×
“The loading of a therapeutic molecule is accomplished by electrostatic interaction or covalent conjugation [17, 61, 62].”
BackgroundTumor-targeted nanomedicines for cancer theranostics
Arranja, A. G., Pathak, V., Lammers, T., & Shi, Y. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.014 · Cited by 246 · cited 1×
“Although effective nanotheranostics for the treatment of brain cancer have been established over the time, most of them are still under investigations [20-23].”
BackgroundGlioma targeting and blood–brain barrier penetration by dual-targeting doxorubincin liposomes
Gao, J.-Q., Lv, Q., Li, L.-M., Tang, X.-J., Li, F.-Z., Hu, Y.-L., & Han, M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.097 · Cited by 224 · cited 1×
“The average duration of survival is even less and fall between 15 to 22 months [5].”
BackgroundApplications of Dendrimers in Drug Delivery Agents, Diagnosis, Therapy, and Detection
Noriega-Luna, B., Godínez, L. A., Rodríguez, F. J., Rodríguez, A., Zaldívar-Lelo de Larrea, G., Sosa-Ferreyra, C. F., Mercado-Curiel, R. F., Manríquez, J., & Bustos, E. (2014) · Journal of Nanomaterials · doi:10.1155/2014/507273 · Cited by 224
Cheng, S.-H., Lee, C.-H., Chen, M.-C., Souris, J. S., Tseng, F.-G., Yang, C.-S., Mou, C.-Y., Chen, C.-T., & Lo, L.-W. (2010) · Journal of Materials Chemistry · doi:10.1039/c0jm00645a · Cited by 222 · cited 1×
“The surface of MSNPs was conjugated with Tf which led to the enhanced recognition of brain glioma cells [103, 104].”
BackgroundShi, Y., van der Meel, R., Theek, B., Oude Blenke, E., Pieters, E. H. E., Fens, M. H. A. M., Ehling, J., Schiffelers, R. M., Storm, G., van Nostrum, C. F., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b00929 · Cited by 214 · cited 1×
“At present, PMs are successfully being applied in preclinical as well as clinical studies [119-122].”
BackgroundNew strategies to deliver anticancer drugs to brain tumors
Laquintana, V., Trapani, A., Denora, N., Wang, F., Gallo, J. M., & Trapani, G. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903167942 · Cited by 214 · cited 2×
“These glial cells are functionalized to insulate and regulate the activity of neuron cells [7].”
BackgroundIn Vitro Models of the Blood–Brain Barrier for the Study of Drug Delivery to the Brain
Wilhelm, I., & Krizbai, I. A. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500046f · Cited by 211 · cited 2×
“The main hurdle for nanotheranostic delivery into the brain is the existence of BBB which restricts the transport of molecules/nanoparticles from blood to brain and vice-versa [63].”
BackgroundMethodBrain tumor-targeted drug delivery strategies
Wei, X., Chen, X., Ying, M., & Lu, W. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.03.001 · Cited by 205 · cited 2×
“, PLA, PLGA and their copolymers which are readily eliminated after normal metabolic pathways [15, 112].”
BackgroundMuthu, M. S., Kutty, R. V., Luo, Z., Xie, J., & Feng, S.-S. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.11.008 · Cited by 193 · cited 1×
“One of which is receptor-mediated endocytosis which delivers both diagnostic and therapeutic agents simultaneously (Figure 3) [11, 62, 71-74].”
BackgroundSelf-citationGary-Bobo, M., Hocine, O., Brevet, D., Maynadier, M., Raehm, L., Richeter, S., Charasson, V., Loock, B., Morère, A., Maillard, P., et al. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.11.045 · Cited by 186
Stephen, Z. R., Kievit, F. M., Veiseh, O., Chiarelli, P. A., Fang, C., Wang, K., Hatzinger, S. J., Ellenbogen, R. G., Silber, J. R., & Zhang, M. (2014) · ACS Nano · doi:10.1021/nn503735w · Cited by 182 · cited 1×
“Recent in-vivo works of MNPs with stimulus responsive function [87], BBB targeted delivery [88] and reversible BBB opening with hyperthermia [89] also suggested the possible application of these nanotheranostics for clinical use.”
BackgroundRuan, S., He, Q., & Gao, H. (2015) · Nanoscale · doi:10.1039/c5nr01408e · Cited by 173 · cited 1×
“In-vivo study proved that glioma targeting of gold nanotheransostics was achieved well with co-localization within neovessels [82].”
BackgroundThe application of mesoporous silica nanoparticle family in cancer theranostics
Feng, Y., Panwar, N., Tng, D. J. H., Tjin, S. C., Wang, K., & Yong, K.-T. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.019 · Cited by 171 · cited 2×
“The surface of MSNPs was conjugated with Tf which led to the enhanced recognition of brain glioma cells [103, 104].”
BackgroundClinical Developments in Nanotechnology for Cancer Therapy
Heidel, J. D., & Davis, M. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0178-7 · Cited by 170 · cited 1×
“Fifth, the loading or encapsulation of therapeutic entities such as small sized hydrophobic molecules, peptide drugs as well as oligonucleotides within the nanosystems enhance their stability as well [19, 30-33].”
BackgroundMagnetic Nanoparticles in Biomedicine: Synthesis, Functionalization and Applications
Frimpong, R. A., & Hilt, J. Z. (2010) · Nanomedicine · doi:10.2217/nnm.10.114 · Cited by 164 · cited 2×
“Owing to the magnetic response, iron oxide core facilitates the magnetic targeted delivery [84, 85].”
BackgroundHuang, X., Zhang, F., Wang, H., Niu, G., Choi, K. Y., Swierczewska, M., Zhang, G., Gao, H., Wang, Z., Zhu, L., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.032 · Cited by 163
Zong, T., Mei, L., Gao, H., Cai, W., Zhu, P., Shi, K., Chen, J., Wang, Y., Gao, F., & He, Q. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500057n · Cited by 160 · cited 1×
“Moreover, most of them are substrates of multidrug resistant(MDR) drug efflux pumps(P-gp) that are active on both BBB and tumor vascular cells [16].”
BackgroundTheranostic nanomedicine for cancer detection and treatment
Fan, Z., Fu, P. P., Yu, H., & Ray, P. C. (2014) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2014.01.001 · Cited by 160 · cited 3×
“The loading of a therapeutic molecule is accomplished by electrostatic interaction or covalent conjugation [17, 61, 62].”
BackgroundTabatabaei, S. N., Girouard, H., Carret, A., & Martel, S. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.027 · Cited by 160 · cited 1×
“Recent in-vivo works of MNPs with stimulus responsive function [87], BBB targeted delivery [88] and reversible BBB opening with hyperthermia [89] also suggested the possible application of these nanotheranostics for clinical use.”
BackgroundSonali, Singh, R. P., Singh, N., Sharma, G., Vijayakumar, M. R., Koch, B., Singh, S., Singh, U., Dash, D., Pandey, B. L., et al. (2016) · Drug Delivery · doi:10.3109/10717544.2016.1162878 · Cited by 159 · cited 2×
“polyethylene glycol (PEG) or D-α-tocopheryl polyethylene glycol-1000 succinate mono ester (TPGS)] which inhibit the release of therapeutic agent within normal tissues and enable them to escape from the reticuloendothelial system (RES); thus, reducing overall systemic toxicity [11-13, 18].”
BackgroundSelf-citationTheranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation
Lammers, T., Koczera, P., Fokong, S., Gremse, F., Ehling, J., Vogt, M., Pich, A., Storm, G., van Zandvoort, M., & Kiessling, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201401199 · Cited by 156 · cited 1×
“Recent in-vivo works of MNPs with stimulus responsive function [87], BBB targeted delivery [88] and reversible BBB opening with hyperthermia [89] also suggested the possible application of these nanotheranostics for clinical use.”
BackgroundKim, S. S., Harford, J. B., Pirollo, K. F., & Chang, E. H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.137 · Cited by 155 · cited 1×
“The higher rates of relapse, general resistance to the treatment, dreadful neurological degeneration, and lower rates of survival make brain cancer one of the most horrendous types of cancer [3].”
BackgroundImage guided therapy: The advent of theranostic agents
Terreno, E., Uggeri, F., & Aime, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.028 · Cited by 153 · cited 1×
“PET can more efficiently characterize brain tumors by investigating metabolic processes such as receptor binding, DNA synthesis or enzyme activity, oxygen metabolism and blood flow [54-57].”
BackgroundMelancon, M. P., Lu, W., Zhong, M., Zhou, M., Liang, G., Elliott, A. M., Hazle, J. D., Myers, J. N., Li, C., & Jason Stafford, R. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.039 · Cited by 139 · cited 1×
“, prepared multi utility gold-based nanoshells with magnetic and optical properties which were further conjugated with targeting moiety and explored for application in neck and head cancer [76].”
BackgroundPhotodynamic therapy of brain tumors—A work in progress
Muller, P. J., & Wilson, B. C. (2006) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20338 · Cited by 137
Sonali, Agrawal, P., Singh, R. P., Rajesh, C. V., Singh, S., Vijayakumar, M. R., Pandey, B. L., & Muthu, M. S. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1094681 · Cited by 133 · cited 1×
“It acts as a physical barrier and is consisting of vascular endothelial cells that adjoin with tight junctions, enzymes, receptors, transporters, and the ATP-dependent, 170-kDa efflux pump P-glycoprotein (P-gp) [10-12].”
BackgroundSelf-citationNanoparticles for Imaging and Treating Brain Cancer
Meyers, J. D., Doane, T., Burda, C., & Basilion, J. P. (2013) · Nanomedicine · doi:10.2217/nnm.12.185 · Cited by 131 · cited 1×
“Such improvements comprise early detection and therapy regimens which shall be more precisely taken up by brain cancer cells and also possess lessened off- target toxicity [24,25].”
BackgroundTherapeutic Nanomedicine for Brain Cancer
Tzeng, S. Y., & Green, J. J. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.38 · Cited by 130 · cited 1×
“In addition, AuNPs can be utilized as the promising candidate for intraoperative tumor margin identification which improved the surgery of brain tumors [80].”
BackgroundMuthu, M. S., & Feng, S.-S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.729576 · Cited by 129 · cited 1×
“One of which is receptor-mediated endocytosis which delivers both diagnostic and therapeutic agents simultaneously (Figure 3) [11, 62, 71-74].”
BackgroundSelf-citationTargeted Imaging and Therapy of Brain Cancer Using Theranostic Nanoparticles
Bhojani, M. S., Dort, M. V., Rehemtulla, A., & Ross, B. D. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100298r · Cited by 129 · cited 1×
“The capacity of nanocarriers to deliver both drug and diagnostic molecules selectively to cancer sites at sufficient levels is an essential determinant of the efficiency of cancer diagnosis and treatment [28,29].”
BackgroundGaillard, P. J., van der Sandt, I. C. J., Voorwinden, L. H., Vu, D., Nielsen, J. L., de Boer, A. G., & Breimer, D. D. (2000) · Pharmaceutical Research · doi:10.1023/a:1026406528530 · Cited by 128 · cited 1×
“, a model of triple co-cultured brain endothelium, astrocytes and pericytes) [65-67].”
BackgroundQuantum dots in nanomedicine: recent trends, advances and unresolved issues
Volkov, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.039 · Cited by 128 · cited 14×
“The nanoprobes targeted to glioblastoma showed an enhanced imaging and Nanotheranostics 2018, Vol. 2 http://www.ntno.org 79 targeting effect in comparison with the clinical product, i.e., MRI contrast gadoliniumdiethylenetriamine penta acetic acid (Gd-DTPA) and fluorescent dye 5-aminolevulinic acid (5-ALA).”
BackgroundInfluentialMartins, S. M., Sarmento, B., Nunes, C., Lúcio, M., Reis, S., & Ferreira, D. (2013) · European journal of pharmaceutics and biopharmaceutics · doi:10.1016/j.ejpb.2013.08.011 · Cited by 127 · cited 1×
“For this purpose, they prepared camptothecin-loaded SLNs for brain targeting and established the beneficial effect of SLNs on brain targeting when compared to the non-encapsulated drug [130].”
Nanotherapeutic approaches for brain cancer management
del Burgo, L. S., Hernández, R. M., Orive, G., & Pedraz, J. L. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.10.001 · Cited by 126
Muthu, M. S., Avinash Kulkarni, S., Liu, Y., & Feng, S.-S. (2012) · Nanomedicine · doi:10.2217/nnm.11.111 · Cited by 120 · cited 6×
“One of which is receptor-mediated endocytosis which delivers both diagnostic and therapeutic agents simultaneously (Figure 3) [11, 62, 71-74].”
BackgroundInfluentialSelf-citationThe treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates
Gajbhiye, V., & Jain, N. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.057 · Cited by 120 · cited 1×
“, have developed polysorbate 80 coated dendrimer of DTX for the treatment of brain tumors and demonstrated the greater in-vitro cytotoxic potential and in-vivo effect on brain tumor [135].”
BackgroundTPGS-chitosan cross-linked targeted nanoparticles for effective brain cancer therapy
Agrawal, P., Singh, R. P., Sonali, Laksmi, K., Sharma, G., Koch, B., Rajesh, C. V., Mehata, A. K., Singh, S. K., Pandey, B. L., et al. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.02.008 · Cited by 119 · cited 2×
“polyethylene glycol (PEG) or D-α-tocopheryl polyethylene glycol-1000 succinate mono ester (TPGS)] which inhibit the release of therapeutic agent within normal tissues and enable them to escape from the reticuloendothelial system (RES); thus, reducing overall systemic toxicity [11-13, 18].”
BackgroundSelf-citationSun, L., Joh, D. Y., Al-Zaki, A., Stangl, M., Murty, S., Davis, J. J., Baumann, B. C., Alonso-Basanta, M., Kao, G. D., Tsourkas, A., et al. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2173 · Cited by 119 · cited 1×
“It was also suggested as a novel contrasting agent for both MRI and CT studies [83].”
BackgroundRGD-TPGS decorated theranostic liposomes for brain targeted delivery
Sonali, Singh, R. P., Sharma, G., Kumari, L., Koch, B., Singh, S. K., Bharti, S., Rajinikanth, P. S., Pandey, B. L., & Muthu, M. S. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.07.058 · Cited by 119 · cited 3×
“polyethylene glycol (PEG) or D-α-tocopheryl polyethylene glycol-1000 succinate mono ester (TPGS)] which inhibit the release of therapeutic agent within normal tissues and enable them to escape from the reticuloendothelial system (RES); thus, reducing overall systemic toxicity [11-13, 18].”
BackgroundSelf-citationRemotely Triggered Nano-Theranostics For Cancer Applications
Sneider, A., VanDyke, D., Paliwal, S., & Rai, P. (2017) · Nanotheranostics · doi:10.7150/ntno.17109 · Cited by 108 · cited 1×
“Finally, nanotheranostics which target molecular biomarkers of brain cancer with advanced designs are likely to contribute to the early diagnosis and therapy of brain cancer [138, 139].”
BackgroundQIN, L., WANG, C.-Z., FAN, H.-J., ZHANG, C.-J., ZHANG, H.-W., LV, M.-H., & CUI, S.-D. (2014) · Oncology Letters · doi:10.3892/ol.2014.2449 · Cited by 105 · cited 2×
“In recent years, dual targeting nanomedicines are also reported for brain-targeted diagnosis and therapy [37-39].”
BackgroundImmunotherapy of malignant brain tumors
Mitchell, D. A., Fecci, P. E., & Sampson, J. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00603.x · Cited by 104 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodChitosan-folate decorated carbon nanotubes for site specific lung cancer delivery
Singh, R. P., Sharma, G., Sonali, Singh, S. K., Bharti, S., Pandey, B. L., Koch, B., & Muthu, M. S. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.03.225 · Cited by 103
Self-citationDendrimer technologies for brain tumor
Mishra, V. K., & Kesharwani, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.006 · Cited by 102 · cited 1×
“Compared with other delivery systems, they often show advantages in size uniformity, reduced macrophage uptake, rapid cellular entry, target ability and more extensive passage across biological membranes by transcytosis [131, 133].”
BackgroundTransferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain
Somani, S., Blatchford, D. R., Millington, O. R., Stevenson, M. L., & Dufès, C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.006 · Cited by 98 · cited 1×
“Further It was suggested that Tf bearing dendrimer could be a promising approach for gene targeted delivery in brain cancer applications [136].”
BackgroundJiang, X., Sha, X., Xin, H., Xu, X., Gu, J., Xia, W., Chen, S., Xie, Y., Chen, L., Chen, Y., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.049 · Cited by 92 · cited 1×
“The nanocarriers targeted to cyclic RGD receptor showed excellent infiltration as well as targeted accumulation into cancer spheroids and revealed the applicability of using 3D models for brain nanotheranostics [69].”
BackgroundSarin, H. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-77 · Cited by 91 · cited 1×
“The therapeutic efficiency of dendrimer was found to be significantly more in inhibiting the growth of RG-2 gliomas up to 24 h [134].”
Theranostic applications of mesoporous silica nanoparticles and their organic/inorganic hybrids
Chen, N., Cheng, S., Souris, J. S., Chen, C.-T., Mou, C., & Lo, L. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20249f · Cited by 86 · cited 1×
“They hydrolyzed in physiological conditions at lower concentrations [101, 102].”
BackgroundCarbon Nanomaterials for Drug Delivery and Cancer Therapy
Chakrabarti, M., Kiseleva, R. Y., Vertegel, A. A., & Ray, S. K. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2015.10614 · Cited by 84 · cited 1×
“Once they are taken up by the cells, they may also interact with proteins and DNA to affect the cellular signaling or mechanism of other therapies [94, 95].”
BackgroundOnoshima, D., Yukawa, H., & Baba, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.08.004 · Cited by 83 · cited 2×
“In future, surface modified, biocompatible and excretable QDs are much awaited [92].”
BackgroundMethodAntiangiogenic therapy in brain tumors
Lakka, S. S., & Rao, J. S. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1457 · Cited by 80 · cited 1×
“Although effective nanotheranostics for the treatment of brain cancer have been established over the time, most of them are still under investigations [20-23].”
BackgroundAgrawal, P., Sonali, Singh, R. P., Sharma, G., Mehata, A. K., Singh, S. K., Rajesh, C. V., Pandey, B. L., Koch, B., & Muthu, M. S. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.01.021 · Cited by 80
Self-citationNanotheranostics: Advanced Nanomedicine for The Integration of Diagnosis and Therapy
Muthu, M. S., Mei, L., & Feng, S. (2014) · Nanomedicine · doi:10.2217/nnm.14.83 · Cited by 79 · cited 3×
“Various diagnostic and therapeutic agents are suffered from modest pharmacokinetics and improper bio-distribution which cause inadequate dissemination into tumors [18,19].”
BackgroundSelf-citationDoxorubicin conjugated phospholipid prodrugs as smart nanomedicine platforms for cancer therapy
Wang, H., Liu, X., Wang, Y., Chen, Y., Jin, Q., & Ji, J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c4tb01984a · Cited by 77 · cited 1×
“They hydrolyzed in physiological conditions at lower concentrations [101, 102].”
BackgroundEffects of transferrin conjugated multi-walled carbon nanotubes in lung cancer delivery
Singh, R. P., Sharma, G., Sonali, Singh, S. K., Patne, S., Pandey, B. L., Koch, B., & Muthu, M. S. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.05.013 · Cited by 76
Self-citationSingh, R. P., Sharma, G., Sonali, Singh, S. K., Mohan Kumar, H., Pandey, B. L., Koch, B., & Muthu, M. S. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.02.011 · Cited by 76 · cited 5×
“CNTs can be considered as allotropes of carbon with slow biodegradation and poor biocompatibility [33].”
BackgroundInfluentialSelf-citationTargeting cancer stem cells by using the nanoparticles
An, S. S. A., Jang, G.-B., Lee, H., Hong, I., & Nam, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s88310 · Cited by 74 · cited 9×
“CSC has been detected in brain cancer besides many other cancers in human.”
BackgroundInfluentialCurrent status of gene therapy for brain tumors
Murphy, A. M., & Rabkin, S. D. (2012) · Translational research · doi:10.1016/j.trsl.2012.11.003 · Cited by 64 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodGene therapy for brain tumors: Basic developments and clinical implementation
Assi, H. H., Candolfi, M., Baker, G. J., Mineharu, Y., Lowenstein, P. R., & Castro, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.08.003 · Cited by 63 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodMulticell tumor spheroids in photodynamic therapy
Madsen, S. J., Sun, C., Tromberg, B. J., Vittorio Cristini, C., Magalhães, N. D., & Hirschberg, H. (2006) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20350 · Cited by 62 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodDoxorubicin-loaded lipid-quantum dot hybrids: Surface topography and release properties
Tian, B., Al-Jamal, W. T., Al‐Jamal, K. T., & Kostarelos, K. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.057 · Cited by 61 · cited 1×
“The technique of avidin-biotin cross-linking is one more important method for conjugating targeting ligand on the surface of QDs [91, 92].”
MethodIN VITRO CHARACTERIZATION OF A TARGETED, DYE-LOADED NANODEVICE FOR INTRAOPERATIVE TUMOR DELINEATION
Orringer, D. A., Koo, Y.-E. L., Chen, T., Kim, G., Hah, H. J., Xu, H., Wang, S., Keep, R. F., Philbert, M. A., Kopelman, R., et al. (2009) · Neurosurgery · doi:10.1227/01.neu.0000344150.81021.aa · Cited by 60 · cited 1×
“, nucleolin, will substantially improve internalization of nanoparticles within glioma cells and enhance the proportion of cells that are labeled by dye-possessing nanoparticles [36].”
BackgroundTransferrin receptor targeted PLA-TPGS micelles improved efficacy and safety in docetaxel delivery
Singh, R. P., Sharma, G., Sonali, Agrawal, P., Pandey, B. L., Koch, B., & Muthu, M. S. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.11.081 · Cited by 56 · cited 2×
“The authors explained that surface-modified G3 PAMAM dendrimers could be promising nanocarriers for lipophilic p-gp substrate drugs [32].”
BackgroundSelf-citationCyclic RGD–Polyethylene Glycol–Polyethylenimine for Intracranial Glioblastoma‐Targeted Gene Delivery
Zhan, C., Meng, Q., Li, Q., Feng, L., Zhu, J., & Lu, W. (2011) · Chemistry - An Asian Journal · doi:10.1002/asia.201100570 · Cited by 55 · cited 1×
“RGD receptor targeted nanoparticles exhibited affinity with U87 cells and aided in target specific gene delivery for intracranial glioblastoma treatment in-vivo [118].”
BackgroundToward Effective Immunotherapy for the Treatment of Malignant Brain Tumors
Mitchell, D. A., & Sampson, J. H. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.003 · Cited by 41 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodNanotechnology Advances in Brain Tumors: The State of the Art
Invernici, G., Cristini, S., Alessandri, G., Navone, S. E., Canzi, L., Tavian, D., Redaelli, C., Acerbi, F., & Parati, E. A. (2010) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489211793979990 · Cited by 39 · cited 2×
“Using anti-transcytosis receptor peptidomimetic antibodies to BBB, brain glioma targeted PEGylated immune nanoparticles were prepared which able to deliver the anti-cancer agents into brain parenchyma without BBB permeability alteration [111, 117].”
BackgroundMethodBrain Tumor Immunotherapy: What have We Learned so Far?
Gool, S. W. V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00098 · Cited by 37
Double-targeted polymersomes and liposomes for multiple barrier crossing
Sánchez-Purrà, M., Ramos, V., Petrenko, V. A., Torchilin, V. P., & Borrós, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.08.001 · Cited by 34 · cited 1×
“In recent years, dual targeting nanomedicines are also reported for brain-targeted diagnosis and therapy [37-39].”
BackgroundDual-ligand α5β1 and α6β4 integrin targeting enhances gene delivery and selectivity to cancer cells
Levine, R. M., & Kokkoli, E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.017 · Cited by 33
Recent strategies to design vascular theranostic nanoparticles
Gupta, M. K., Lee, Y., Boire, T. C., Lee, J.-B., Kim, W. S., & Sung, H. (2017) · Nanotheranostics · doi:10.7150/ntno.18531 · Cited by 32 · cited 1×
“Finally, nanotheranostics which target molecular biomarkers of brain cancer with advanced designs are likely to contribute to the early diagnosis and therapy of brain cancer [138, 139].”
BackgroundUpconversion nanoparticle as a theranostic agent for tumor imaging and therapy
Fang, W.-K., & Wei, Y. (2016) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545816300068 · Cited by 31 · cited 2×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
BackgroundMethodPharmacogenomics of Brain Cancer and Personalized Medicine in Malignant Gliomas
Mehrian‐Shai, R., Reichardt, J. K. V., & Chen, T. C. (2008) · Future Oncology · doi:10.2217/14796694.4.4.525 · Cited by 30 · cited 1×
“Oligodendrogliomas are a kind of glioma that is believed to be originated from the oligodendrocytes of the brain or a glial precursor cell [8].”
BackgroundImmunotherapy for glioblastoma: concepts and challenges
Weiß, T., Weller, M., & Roth, P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000249 · Cited by 29 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodCurrent Role of Anti-Angiogenic Strategies for Glioblastoma
Thomas, A. A., & Omuro, A. M. P. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0308-2 · Cited by 27 · cited 1×
“development of modern technology, other treatment methods have also been studied such as angiogenesis inhibitors therapy [42, 43], immune therapy [44-47], photodynamic therapy [48-50], hyperthermia therapy [51], and gene therapy [52,53].”
MethodShi, Y., Kunjachan, S., Wu, Z., Gremse, F., Moeckel, D., van Zandvoort, M. A. M. J., Kiessling, F. M., Storm, G., van Nostrum, C. F., Hennink, W. E., et al. (2015) · Nanomedicine · doi:10.2217/nnm.14.170 · Cited by 21 · cited 1×
“At present, PMs are successfully being applied in preclinical as well as clinical studies [119-122].”
BackgroundNanoparticles in endothelial theranostics
Zapotoczny, S., Szczubiałka, K., & Nowakowska, M. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.05.018 · Cited by 18 · cited 1×
“PET can more efficiently characterize brain tumors by investigating metabolic processes such as receptor binding, DNA synthesis or enzyme activity, oxygen metabolism and blood flow [54-57].”
Background
Cited by
Recent advances and prospects of carbon dots in phototherapy
Li, B., Zhao, S., Huang, L., Wang, Q., Xiao, J., & Lan, M. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127245 · Cited by 214
Recent advances and prospects of carbon dots in cancer nanotheranostics
Jia, Q., Zhao, Z., Liang, K., Nan, F., Li, Y., Wang, J., Ge, J., & Wang, P. (2020) · Materials Chemistry Frontiers · doi:10.1039/c9qm00667b · Cited by 161
Nicolson, F., Andreiuk, B., Andreou, C., Hsu, H.-T., Rudder, S., & Kircher, M. F. (2019) · Theranostics · doi:10.7150/thno.36321 · Cited by 152
“While theranostic approaches to improve diagnosis and cure rates of various cancer types is a very active area of research with multiple approaches being tested [4-18], complete tumor resection, which can only be achieved via complete tumor visualization, is deemed the most important factor for the outcome of GBM pati…”
BackgroundA Review on Theranostics: An Approach to Targeted Diagnosis and Therapy
Shrivastava, S., Jain, S., Kumar, D., Soni, S. L., & Sharma, M. (2019) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v7i2.463 · Cited by 53
“Second, nanocarriers are competent enough to improve the pharmacokinetics and to enhance the biodistribution of existing therapeutic moieties to the target tissues, so that can improve efficiency.(8)”
Background
Metadata
- Authors
- Sonali, Viswanadh, M. K., Singh, R. P., Agrawal, P., Mehata, A. K., Pawde, D. M., Narendra, Sonkar, R., & Muthu, M. S.
- Venue
- Nanotheranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 2
- Issue
- 1
- Pages
- 70-86
- ISSN
- 2206-7418 (ISSN-L)
- OpenAlex
- W2771352686
- Cited by
- 169
- References
- 132
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.